LHDX Lucira Health, Inc. Stock Quote

LHDX [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-0.60	Insider Own	35.90%	Shs Outstand	44.92M	Perf Week	-22.32%
Market Cap	318.93M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	27.33%	Shs Float	36.12M	Perf Month	-50.28%
Income	-22.20M	PEG	-	EPS next Q	-0.38	Inst Own	35.15%	Short Float	1.72%	Perf Quarter	-
Sales	0.27M	P/S	1185.62	EPS this Y	-29.50%	Inst Trans	-	Short Ratio	0.83	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	42.30%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	1.52	P/C	4.67	EPS next 5Y	-	ROE	-	52W Range	6.66 - 37.99	Perf YTD	-71.58%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-81.52%	Beta	-
Dividend %	-	Quick Ratio	12.00	Sales past 5Y	-	Gross Margin	-	52W Low	5.39%	ATR	1.14
Employees	57	Current Ratio	12.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	32.17	Volatility	10.07% 12.43%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.64	Prev Close	7.10
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	749.27K	Price	7.02
Recom	2.00	SMA20	-27.22%	SMA50	-56.24%	SMA200	-58.01%	Volume	92,140	Change	-1.14%

Apr-13-21

Downgrade

BofA Securities

Neutral → Underperform

Mar-02-21

Initiated

William Blair

Outperform

Mar-02-21

Initiated

BofA Securities

Neutral

$22

Apr-22-21 03:49PM	For the First Time Ever, NBA Fans Can Test Themselves for COVID-19 Before Attending a Live Game. Testing Program Debuts in San Francisco Bay Area this Friday with LUCIRA Check It COVID-19 At-Home Test Business Wire
Apr-13-21 08:12PM	Covid Test Maker Cue Health Taps Morgan Stanley, Goldman for IPO Bloomberg -18.52%
02:09PM	Why Lucira Health Stock Is Plunging Today Motley Fool
Apr-12-21 05:30PM	Why Lucira Health Stock Skyrocketed Today Motley Fool +27.01%
07:00AM	FDA Authorizes First Single-Use, PCR Quality Over the Counter (OTC) LUCIRA CHECK IT COVID-19 At-Home Test. Available Now. Business Wire
Apr-09-21 06:00AM	LUCIRA COVID-19 Test Kit Identifies Viral Variants Business Wire
Feb-11-21 06:00AM	U.S. Physicians Can Now Order Lucira Health Self-Administered, Lab Quality, COVID-19 Molecular Test for Home or Office Business Wire +9.64%
Feb-09-21 04:05PM	Lucira Health Announces Closing of its Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Feb-05-21 05:26PM	The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market Barrons.com
Feb-04-21 11:27PM	Lucira Health Announces Pricing of Its Upsized Initial Public Offering Business Wire

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EPIQ Capital Group, LLC	10% Owner	Feb 05	Buy	17.00	3,461,764	58,849,988	3,461,764	Feb 09 06:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience